{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:13:35Z","timestamp":1792725215775,"version":"4.5.0"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejphar.2024.177083","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T22:16:44Z","timestamp":1730326604000},"page":"177083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["RNAi in psoriasis: A melodic exploration of miRNA, shRNA, and amiRNA with a spotlight on siRNA"],"prefix":"10.1016","volume":"985","author":[{"given":"Japneet Singh","family":"Purewal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-0705","authenticated-orcid":false,"given":"Gaurav Mahesh","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.177083_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/btm2.10083","article-title":"Ionic liquids for addressing unmet needs in healthcare","volume":"3","author":"Agatemor","year":"2018","journal-title":"Bioeng Transl Med"},{"issue":"7 55","key":"10.1016\/j.ejphar.2024.177083_bib2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s12276-023-00998-y","article-title":"Where should siRNAs go: applicable organs for siRNA drugs","volume":"55","author":"Ahn","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"7 55","key":"10.1016\/j.ejphar.2024.177083_bib3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s12276-023-00998-y","article-title":"Where should siRNAs go: applicable organs for siRNA drugs","volume":"55","author":"Ahn","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejphar.2024.177083_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering siRNA therapeutics: challenges and strategies","volume":"21","author":"Ali Zaidi","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejphar.2024.177083_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177083_bib6","first-page":"23","article-title":"Genetic background of psoriasis","volume":"4","author":"Alshobaili","year":"2010","journal-title":"Int. J. Health Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.sjbs.2012.08.001","article-title":"RNA interference: a futuristic tool and its therapeutic applications","volume":"19","author":"Ambesajir","year":"2012","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejphar.2024.177083_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.gt.3302726","article-title":"Target selectivity in mRNA silencing","volume":"13","author":"Aronin","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejphar.2024.177083_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.abd.2021.03.001","article-title":"Phototherapy","volume":"96","author":"Barros","year":"2021","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.ejphar.2024.177083_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymeth.2016.04.003","article-title":"Guidelines for the optimal design of miRNA-based shRNAs","volume":"103","author":"Bofill-De Ros","year":"2016","journal-title":"Methods"},{"key":"10.1016\/j.ejphar.2024.177083_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.celrep.2018.12.054","article-title":"Structural differences between pri-miRNA paralogs promote alternative Drosha cleavage and expand target repertoires","volume":"26","author":"Bofill-De Ros","year":"2019","journal-title":"Cell Rep."},{"issue":"1 6","key":"10.1016\/j.ejphar.2024.177083_bib13","first-page":"1","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2024.177083_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nchembio839","article-title":"RNAi therapeutics: a potential new class of pharmaceutical drugs","volume":"2","author":"Bumcrot","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejphar.2024.177083_bib15","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.4049\/jimmunol.169.9.5196","article-title":"Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference","volume":"169","author":"Capodici","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2024.177083_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122526","article-title":"The genetic basis of psoriasis","volume":"18","author":"Capon","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and Mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2024.177083_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1517\/14656566.2014.875159","article-title":"New topical treatments for psoriasis","volume":"15","author":"Chiricozzi","year":"2014","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2024.177083_bib19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbrc.2006.02.049","article-title":"Chemical modification of siRNAs to improve serum stability without loss of efficacy","volume":"342","author":"Choung","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2024.177083_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","article-title":"Psoriasis: from pathogenesis to targeted therapies","volume":"54","author":"Conrad","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.ejphar.2024.177083_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.humimm.2017.02.008","article-title":"NFKBIZ in Psoriasis: assessing the association with gene polymorphisms and report of a new transcript variant","volume":"78","author":"Coto-Segura","year":"2017","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ejphar.2024.177083_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2024.177083_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int. J. Biomed. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2013.04.021","article-title":"Topical delivery of anti-TNF\u03b1 siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo","volume":"170","author":"Desai","year":"2013","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2024.177083_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.cgt.7700931","article-title":"siRNA-based approaches in cancer therapy","volume":"13","author":"Devi","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejphar.2024.177083_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2020.04.038","article-title":"Topical delivery of siRNA into skin using ionic liquids","volume":"323","author":"Dharamdasani","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2024.177083_bib27","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ijpharm.2012.10.035","article-title":"Ionic liquids as ingredients in topical drug delivery systems","volume":"441","author":"Dobler","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2024.177083_bib28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: siRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib29","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/bmj.328.7450.1245","article-title":"RNA interference","volume":"328","author":"Downward","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2024.177083_bib30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.177083_bib31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.addr.2009.04.005","article-title":"Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape","volume":"61","author":"Endoh","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2024.177083_bib32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nrg3074","article-title":"Non-coding RNAs in human disease","volume":"12","author":"Esteller","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejphar.2024.177083_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114444","article-title":"Application of aptamer-drug delivery system in the therapy of breast cancer","volume":"161","author":"Fan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2024.177083_bib34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molcel.2015.08.015","article-title":"The menu of features that define primary MicroRNAs and enable de novo design of MicroRNA genes","volume":"60","author":"Fang","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2024.177083_bib35","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1242\/dev.005629","article-title":"The growing catalog of small RNAs and their association with distinct Argonaute\/Piwi family members","volume":"135","author":"Farazi","year":"2008","journal-title":"Development"},{"key":"10.1016\/j.ejphar.2024.177083_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18053\/jctres.02.201603.005","article-title":"The role of TNF-\u03b1 in rheumatoid arthritis: a focus on regulatory T cells","volume":"2","author":"Farrugia","year":"2016","journal-title":"J Clin Transl Res"},{"key":"10.1016\/j.ejphar.2024.177083_bib37","first-page":"112","article-title":"RNA Intereference: a powerful laboratory tool and its therapeutic implications","volume":"10","author":"Felekkis","year":"2006","journal-title":"Hippokratia"},{"key":"10.1016\/j.ejphar.2024.177083_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.omtn.2020.06.006","article-title":"Cell type impacts accessibility of mRNA to silencing by RNA interference","volume":"21","author":"Ferguson","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2024.177083_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrg2290","article-title":"Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?","volume":"9","author":"Filipowicz","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejphar.2024.177083_bib40","series-title":"Brenner's Encyclopedia of Genetics","first-page":"221","article-title":"Gene silencing","author":"Filipowicz","year":"2013"},{"key":"10.1016\/j.ejphar.2024.177083_bib41","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.177083_bib42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/ced.12356","article-title":"Effect of psoriasis activity on epidermal growth factor (EGF) and the concentration of soluble EGF receptor in serum and plaque scales","volume":"39","author":"Flisiak","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2024.177083_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41598-019-57289-8","article-title":"Endogenous and artificial miRNAs explore a rich variety of conformations: a potential relationship between secondary structure and biological functionality","volume":"10","author":"Gangemi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2024.177083_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.735124","article-title":"Cognitive process of psoriasis and its comorbidities: from epidemiology to genetics","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejphar.2024.177083_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12060539","article-title":"Review: local tumor necrosis factor-\u03b1 inhibition in inflammatory bowel disease","volume":"12","author":"Gareb","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2024.177083_bib46","first-page":"187","article-title":"Therapeutic siRNA: principles, challenges, and strategies","volume":"85","author":"Gavrilov","year":"2012","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.ejphar.2024.177083_bib47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1261\/rna.1894510","article-title":"Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity","volume":"16","author":"Ge","year":"2010","journal-title":"RNA"},{"key":"10.1016\/j.ejphar.2024.177083_bib48","unstructured":"Gene Expression [WWW Document], n.d. URL https:\/\/www.genome.gov\/genetics-glossary\/Gene-Expression (accessed 12.26.23)."},{"key":"10.1016\/j.ejphar.2024.177083_bib49","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2024.177083_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib51","first-page":"97","article-title":"Current developments in the immunology of psoriasis","volume":"93","author":"Gr\u00e4n","year":"2020","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.ejphar.2024.177083_bib52","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejphar.2024.177083_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-009-9141-y","article-title":"Multifunctional nanocomplexes for gene transfer and gene therapy","volume":"26","author":"Hart","year":"2010","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.ejphar.2024.177083_bib54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/JID.2015.409","article-title":"microRNAs in Psoriasis","volume":"136","author":"Hawkes","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2024.177083_bib55","article-title":"Predicting siRNA efficacy based on multiple selective siRNA representations and their combination at score level","volume":"7","author":"He","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2024.177083_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1 9","key":"10.1016\/j.ejphar.2024.177083_bib57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2024.177083_bib58","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/mt.2009.141","article-title":"Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model","volume":"17","author":"Jakobsen","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2024.177083_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib60","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/exd.14871","article-title":"The role of microRNA in psoriasis: a review","volume":"32","author":"Jiang","year":"2023","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2024.177083_bib61","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/med.21291","article-title":"Keratin 17: a critical player in the pathogenesis of psoriasis","volume":"34","author":"Jin","year":"2014","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejphar.2024.177083_bib62","doi-asserted-by":"crossref","first-page":"E5825","DOI":"10.1073\/pnas.1509971112","article-title":"I\u03baB\u03b6 is a key driver in the development of psoriasis","volume":"112","author":"Johansen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2024.177083_bib63","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/mt.2011.294","article-title":"Action and reaction: the biological response to siRNA and its delivery vehicles","volume":"20","author":"Kanasty","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2024.177083_bib64","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1021\/mp400644e","article-title":"Prolongation of life in rats with malignant glioma by intranasal siRNA\/drug codelivery to the brain with cell-penetrating peptide-modified micelles","volume":"11","author":"Kanazawa","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejphar.2024.177083_bib65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12929-023-00981-9","article-title":"Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges","volume":"30","author":"Kang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib66","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2024.177083_bib67","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/09546634.2017.1309349","article-title":"Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects","volume":"28","author":"Khalil","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.ejphar.2024.177083_bib68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molmed.2009.09.001","article-title":"Strategies for targeted nonviral delivery of siRNAs in vivo","volume":"15","author":"Kim","year":"2009","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejphar.2024.177083_bib69","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nrm2632","article-title":"Biogenesis of small RNAs in animals","volume":"10","author":"Kim","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2024.177083_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1640","article-title":"Artificial miRNAs as therapeutic tools: challenges and opportunities","volume":"12","author":"Kotowska-Zimmer","year":"2021","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.ejphar.2024.177083_bib71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.ejphar.2024.177083_bib72","article-title":"The emerging potential of siRNA nanotherapeutics in treatment of arthritis","volume":"18","author":"Kumari","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib73","doi-asserted-by":"crossref","first-page":"20234","DOI":"10.1021\/acsomega.3c01703","article-title":"Emergence of small interfering RNA-based gene drugs for various diseases","volume":"8","author":"Kurakula","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejphar.2024.177083_bib74","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2024.177083_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2011.02.006","article-title":"Pulmonary delivery of therapeutic siRNA","volume":"64","author":"Lam","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2024.177083_bib76","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.ejphar.2024.177083_bib77","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/15476286.2017.1405210","article-title":"Emerging roles of DROSHA beyond primary microRNA processing","volume":"15","author":"Lee","year":"2018","journal-title":"RNA Biol."},{"key":"10.1016\/j.ejphar.2024.177083_bib78","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2024.177083_bib79","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1038\/sj.emboj.7600385","article-title":"MicroRNA genes are transcribed by RNA polymerase II","volume":"23","author":"Lee","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2024.177083_bib80","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1038\/mtna.2013.46","article-title":"Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier","volume":"2","author":"Lennox","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2024.177083_bib81","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00268-008-9836-x","article-title":"MicroRNAs: control and loss of control in human physiology and disease","volume":"33","author":"Li","year":"2009","journal-title":"World J. Surg."},{"key":"10.1016\/j.ejphar.2024.177083_bib82","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2012.08.014","article-title":"Single-stranded siRNAs activate RNAi in animals","volume":"150","author":"Lima","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2024.177083_bib83","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semcdb.2021.06.018","article-title":"Keratin 17 in psoriasis: current understanding and future perspectives","volume":"128","author":"Lin","year":"2022","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2024.177083_bib84","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3748\/wjg.v13.i4.497","article-title":"Impact of tiny miRNAs on cancers","volume":"13","author":"Liu","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2024.177083_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2024.177083_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb6049","article-title":"Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations","volume":"6","author":"Mandal","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejphar.2024.177083_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005468.pub2","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev CD005468"},{"key":"10.1016\/j.ejphar.2024.177083_bib88","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","article-title":"Adeno-associated virus (AAV) cell entry: structural insights","volume":"30","author":"Meyer","year":"2022","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ejphar.2024.177083_bib89","first-page":"141","article-title":"Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown","volume":"629","author":"Moore","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2024.177083_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1393646","article-title":"Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review","volume":"15","author":"Motamedi","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejphar.2024.177083_bib91","first-page":"493","article-title":"siRNA delivery by magnetofection","volume":"10","author":"Mykhaylyk","year":"2008","journal-title":"Curr. Opin. Mol. Therapeut."},{"key":"10.1016\/j.ejphar.2024.177083_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2012.00102","article-title":"SiRNA design software for a target gene-specific RNA interference","volume":"3","author":"Naito","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejphar.2024.177083_bib93","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2017.10.034","article-title":"Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis","volume":"268","author":"Nemati","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2024.177083_bib94","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O'Brien","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2024.177083_bib95","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.05.008","article-title":"The current landscape of psoriasis genetics in 2020","volume":"99","author":"Ogawa","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040907","article-title":"Liposomal drug delivery systems and anticancer drugs","volume":"23","author":"Olusanya","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2024.177083_bib97","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1261\/rna.7231505","article-title":"Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome","volume":"11","author":"Orban","year":"2005","journal-title":"RNA"},{"key":"10.1016\/j.ejphar.2024.177083_bib98","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5455\/msm.2022.33.40-43","article-title":"Serum levels of tumor necrosis factor - alpha in patients with psoriasis","volume":"34","author":"Ovcina-Kurtovic","year":"2022","journal-title":"Mater Sociomed"},{"key":"10.1016\/j.ejphar.2024.177083_bib99","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5114\/reum.2022.120752","article-title":"The role of HLA-Cw6 in psoriasis and psoriatic arthritis","volume":"60","author":"Owczarek","year":"2022","journal-title":"Reumatologia"},{"key":"10.1016\/j.ejphar.2024.177083_bib100","author":"Padda","year":"2024","journal-title":"Small Interfering RNA (siRNA) Therapy"},{"key":"10.1016\/j.ejphar.2024.177083_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910273","article-title":"Tumor necrosis factor's pathway in crohn's disease: potential for intervention","volume":"22","author":"Pagnini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109341","article-title":"An update on emerging immunological targets and their inhibitors in the treatment of psoriasis","volume":"113","author":"Parab","year":"2022","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejphar.2024.177083_bib103","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor necrosis factor-\u03b1 signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.ejphar.2024.177083_bib104","article-title":"siRNA therapeutics and its challenges: recent advances in effective delivery for cancer therapy","volume":"7","author":"Paul","year":"2022","journal-title":"Open"},{"key":"10.1016\/j.ejphar.2024.177083_bib105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/ph6030287","article-title":"RNAi therapeutics in autoimmune disease","volume":"6","author":"Pauley","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2024.177083_bib106","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/gt.2011.56","article-title":"Special delivery: targeted therapy with small RNAs","volume":"18","author":"Peer","year":"2011","journal-title":"Gene Ther."},{"issue":"1 1","key":"10.1016\/j.ejphar.2024.177083_bib107","first-page":"1","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2024.177083_bib108","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2741\/2865","article-title":"Protein interactions and complexes in human microRNA biogenesis and function","volume":"13","author":"Perron","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejphar.2024.177083_bib109","unstructured":"Psoriasis: Learn More \u2013 Oral medications and injections - InformedHealth.org - NCBI Bookshelf [WWW Document], n.d. URL https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK435704\/(accessed 9.14.24)."},{"key":"10.1016\/j.ejphar.2024.177083_bib110","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2174\/0113894501277656231128060242","article-title":"Deciphering the function of new therapeutic targets and prospective biomarkers in the management of psoriasis","volume":"24","author":"Purewal","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2024.177083_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175882","article-title":"Glaucoma: novel antifibrotic therapeutics for the trabecular meshwork","volume":"954","author":"Qin","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177083_bib112","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"key":"10.1016\/j.ejphar.2024.177083_bib113","doi-asserted-by":"crossref","DOI":"10.1038\/nsmb0906-754","article-title":"L(ou)sy miRNA targets?","author":"Rajewsky","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejphar.2024.177083_bib114","doi-asserted-by":"crossref","first-page":"18513","DOI":"10.1073\/pnas.1313491110","article-title":"Keratins as the main component for the mechanical integrity of keratinocytes","volume":"110","author":"Ramms","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2024.177083_bib115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/pcmedi\/pbz011","article-title":"Genetics of psoriasis: a basis for precision medicine","volume":"2","author":"Ran","year":"2019","journal-title":"Precis Clin Med"},{"key":"10.1016\/j.ejphar.2024.177083_bib116","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","article-title":"siRNA vs. shRNA: similarities and differences","volume":"61","author":"Rao","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2024.177083_bib117","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177083_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib119","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1016\/j.biomaterials.2013.04.060","article-title":"A review of the current status of siRNA nanomedicines in the treatment of cancer","volume":"34","author":"Resnier","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejphar.2024.177083_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112297","article-title":"Old and new biological therapies for psoriasis","volume":"18","author":"R\u00f8nholt","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for siRNA therapeutics: from bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2024.177083_bib122","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2016.07.003","article-title":"Advances in psoriasis physiopathology and treatments: up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS)","volume":"239","author":"Sala","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2024.177083_bib123","doi-asserted-by":"crossref","DOI":"10.2174\/0113816128330298240708110336","article-title":"New insights in psoriasis management using herbal drug nanocarriers","author":"Salgaonkar","year":"2024","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejphar.2024.177083_bib124","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/sj.gt.3302777","article-title":"A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium","volume":"13","author":"Santel","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejphar.2024.177083_bib125","first-page":"79","article-title":"A brief summary of clinical types of psoriasis","volume":"3","author":"Sarac","year":"2016","journal-title":"North Clin Istanb"},{"key":"10.1016\/j.ejphar.2024.177083_bib126","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2024.177083_bib127","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2024.177083_bib128","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2006.02.033","article-title":"Altered keratin 17 peptide ligands inhibit in vitro proliferation of keratinocytes and T cells isolated from patients with psoriasis","volume":"54","author":"Shen","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2024.177083_bib129","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1093\/nar\/gky306","article-title":"Dicer cleaves 5\u2019-extended microRNA precursors originating from RNA polymerase II transcription start sites","volume":"46","author":"Sheng","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2024.177083_bib130","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/jid.2011.222","article-title":"IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms","volume":"131","author":"Shi","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2024.177083_bib131","unstructured":"Study Details | A Phase 1\/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH | ClinicalTrials.gov [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT02352493?term=RNAi.therapeutics&page=2&rank=19 (accessed 9.21.24)."},{"key":"10.1016\/j.ejphar.2024.177083_bib132","unstructured":"Study Details | Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement | ClinicalTrials.gov [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT00882180?term=RNAi.therapeutics&page=1&rank=1 (accessed 9.21.24)."},{"key":"10.1016\/j.ejphar.2024.177083_bib133","unstructured":"Study Details | Intratumoral PH-762 for Cutaneous Carcinoma | ClinicalTrials.gov [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT06014086?term=RNAi.therapeutics&page=1&rank=7 (accessed 9.21.24)."},{"key":"10.1016\/j.ejphar.2024.177083_bib134","unstructured":"Study Details | Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis | ClinicalTrials.gov [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT01981837?term=RNAi.therapeutics&page=2&rank=15 (accessed 9.21.24)."},{"key":"10.1016\/j.ejphar.2024.177083_bib135","unstructured":"Study Details | Safety Study of CALAA-01 to Treat Solid Tumor Cancers | ClinicalTrials.gov [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT00689065?term=RNAi.therapeutics&page=2&rank=17 (accessed 9.21.24)."},{"key":"10.1016\/j.ejphar.2024.177083_bib136","unstructured":"Study Details | Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients | ClinicalTrials.gov [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT04555486?term=RNAi.therapeutics&page=1&rank=9 (accessed 9.21.24)."},{"key":"10.1016\/j.ejphar.2024.177083_bib137","unstructured":"Study Details | The First-in-human Study of SRN-001 in Healthy Participants | ClinicalTrials.gov [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT05984992?term=RNAi.therapeutics&page=1&rank=2 (accessed 9.21.24)."},{"key":"10.1016\/j.ejphar.2024.177083_bib138","article-title":"siRNA based drug design, quality, delivery and clinical translation","volume":"29","author":"Subhan","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejphar.2024.177083_bib139","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2021.08.039","article-title":"TNF\u03b1 siRNA delivery by nanoparticles and photochemical internalization for psoriasis topical therapy","volume":"338","author":"Suzuki","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2024.177083_bib140","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2024.177083_bib141","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79242-w","article-title":"Novel use of a chemically modified siRNA for robust and sustainable in vivo gene silencing in the retina","volume":"10","author":"Taniguchi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2024.177083_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/nano7040077","article-title":"siRNA delivery strategies: a comprehensive review of recent developments","volume":"7","author":"Tatiparti","year":"2017","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejphar.2024.177083_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12051035","article-title":"PSORS1 locus genotyping profile in psoriasis: a pilot case-control study","volume":"12","author":"Tawfik","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejphar.2024.177083_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.644718","article-title":"Insight into the prospects for RNAi therapy of cancer","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177083_bib145","first-page":"367","article-title":"Understanding psoriasis: role of miRNAs","volume":"9","author":"Timis","year":"2018","journal-title":"Biomed Rep"},{"key":"10.1016\/j.ejphar.2024.177083_bib146","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/jpet.122.001234","article-title":"RNAi-based therapeutics and novel RNA bioengineering technologies","volume":"384","author":"Traber","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.177083_bib147","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/ncomms8001","article-title":"Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci","volume":"6","author":"Tsoi","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2024.177083_bib148","first-page":"393","article-title":"RNA interference therapeutics for tumor therapy: promising work in progress","author":"Tsujiuchi","year":"2014","journal-title":"Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition"},{"key":"10.1016\/j.ejphar.2024.177083_bib149","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","article-title":"Endosomal escape pathways for delivery of biologicals","volume":"151","author":"Varkouhi","year":"2011","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2024.177083_bib150","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s13346-020-00723-6","article-title":"Nanostructured lipid carrier co-delivering tacrolimus and TNF-\u03b1 siRNA as an innovate approach to psoriasis","volume":"10","author":"Viegas","year":"2020","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.ejphar.2024.177083_bib151","first-page":"367","article-title":"Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics","volume":"1","author":"Vorhies","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.ejphar.2024.177083_bib152","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejphar.2024.177083_bib153","first-page":"520","article-title":"Recent advances on the roles of epidermal growth factor receptor in psoriasis","volume":"11","author":"Wang","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ejphar.2024.177083_bib154","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2024.177083_bib155","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ymthe.2023.09.012","article-title":"Optimal delivery of RNA interference by viral vectors for cancer therapy","volume":"31","author":"Wong","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2024.177083_bib156","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122684","article-title":"Molecular mechanisms and management of a cutaneous inflammatory disorder: psoriasis","volume":"18","author":"Woo","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177083_bib157","first-page":"120","article-title":"The role of exportin-5 in MicroRNA biogenesis and cancer","volume":"16","author":"Wu","year":"2018","journal-title":"Dev. Reprod. Biol."},{"key":"10.1016\/j.ejphar.2024.177083_bib158","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1208\/s12248-009-9140-1","article-title":"Lipidic systems for in vivo siRNA delivery","volume":"11","author":"Wu","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.ejphar.2024.177083_bib159","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1097\/CM9.0000000000001197","article-title":"Small interfering RNA targeting of keratin 17 reduces inflammation in imiquimod-induced psoriasis-like dermatitis","volume":"133","author":"Xiao","year":"2020","journal-title":"Chin. Med. J."},{"issue":"1 8","key":"10.1016\/j.ejphar.2024.177083_bib160","first-page":"1","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2024.177083_bib161","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jid.2017.05.015","article-title":"Nrf2 promotes keratinocyte proliferation in psoriasis through up-regulation of keratin 6, keratin 16, and keratin 17","volume":"137","author":"Yang","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2024.177083_bib162","article-title":"Tristetraprolin gene single-nucleotide polymorphisms and mRNA level in patients with rheumatoid arthritis","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177083_bib163","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4939-8624-8_4","article-title":"In vitro system for coupling RNAP II transcription to primary microRNA processing and a three-way system for RNAP II transcription\/splicing\/microRNA processing","volume":"1823","author":"Yin","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2024.177083_bib164","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154\u2013155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2024.177083_bib165","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1208\/s12248-009-9096-1","article-title":"Targeted delivery systems for oligonucleotide therapeutics","volume":"11","author":"Yu","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.ejphar.2024.177083_bib166","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1073\/pnas.1403995111","article-title":"Ionic liquids as a class of materials for transdermal delivery and pathogen neutralization","volume":"111","author":"Zakrewsky","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2024.177083_bib167","first-page":"641","article-title":"Novel functions for small RNA molecules","volume":"11","author":"Zhang","year":"2009","journal-title":"Curr. Opin. Mol. Therapeut."},{"key":"10.1016\/j.ejphar.2024.177083_bib168","article-title":"The pro-inflammatory cytokine IL-22 up-regulates keratin 17 expression in keratinocytes via STAT3 and ERK1\/2","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.177083_bib169","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jconrel.2014.04.044","article-title":"Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics","volume":"193","author":"Zhou","year":"2014","journal-title":"J. Contr. Release"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924007738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924007738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T01:29:05Z","timestamp":1733621345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924007738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":169,"alternative-id":["S0014299924007738"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177083","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNAi in psoriasis: A melodic exploration of miRNA, shRNA, and amiRNA with a spotlight on siRNA","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177083"}}